구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Autologous cytokine-induced killer cell (Autologous cytokine-induced killer cell) Biohaven Pharmaceuticals, Inc.·Small Cell Lung Cancer 46 trials |
|---|---|
Overview Program | Autologous cytokine-induced killer cell |
Overview Company | Biohaven Pharmaceuticals, Inc. |
Overview Modality | CGT |
Overview Target | Small Cell Lung Cancer |
Overview Indication | Small Cell Lung Cancer |
Overview Phase | PHASE_3 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Vector | retroviral vector encoding human SAP cDNA before transfer into sublethally irradiated Sap- |
MoA Mechanism | CAR T-cell-mediated side effects is of great relevance |
MoA Biomarker | PD-1 expression |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Randomized pilot study of camrelizumab with or without autologous cytokine-induced killer cells in refractory clear cell renal cell carcinoma.. Clear cell renal cell carcinoma (ccRCC) remains a challenging malignancy to treat, with immune checkpoint inhibitors (ICIs) revolutionizing patient management. This pilot study, evaluated the efficacy and safety of combination therapy comprising camrelizum… |
Toxicology CRS | Reported |
Clinical Safety signal | Randomized pilot study of camrelizumab with or without autologous cytokine-induced killer cells in refractory clear cell renal cell carcinoma.. Clear cell renal cell carcinoma (ccRCC) remains a challenging malignancy to treat, with immune checkpoint inhibitors (ICIs) revolutionizing patient management. This pilot study, evaluated the efficacy and safety of combination therapy comprising camrelizum… |
Clinical Program phase | PHASE_3 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Autologous cytokine-induced killer cell (Autologous cytokine-induced killer cell) Biohaven Pharmaceuticals, Inc.·Small Cell Lung Cancer 46 trials |
|---|---|
Overview Program | Autologous cytokine-induced killer cell |
Overview Company | Biohaven Pharmaceuticals, Inc. |
Overview Modality | CGT |
Overview Target | Small Cell Lung Cancer |
Overview Indication | Small Cell Lung Cancer |
Overview Phase | PHASE_3 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Vector | retroviral vector encoding human SAP cDNA before transfer into sublethally irradiated Sap- |
MoA Mechanism | CAR T-cell-mediated side effects is of great relevance |
MoA Biomarker | PD-1 expression |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Randomized pilot study of camrelizumab with or without autologous cytokine-induced killer cells in refractory clear cell renal cell carcinoma.. Clear cell renal cell carcinoma (ccRCC) remains a challenging malignancy to treat, with immune checkpoint inhibitors (ICIs) revolutionizing patient management. This pilot study, evaluated the efficacy and safety of combination therapy comprising camrelizum… |
Toxicology CRS | Reported |
Clinical Safety signal | Randomized pilot study of camrelizumab with or without autologous cytokine-induced killer cells in refractory clear cell renal cell carcinoma.. Clear cell renal cell carcinoma (ccRCC) remains a challenging malignancy to treat, with immune checkpoint inhibitors (ICIs) revolutionizing patient management. This pilot study, evaluated the efficacy and safety of combination therapy comprising camrelizum… |
Clinical Program phase | PHASE_3 |
추천 비교
추천 비교